




RealRate

PHARMACEUTICAL 2025

Sonnet Biotherapeutics Holdings Inc
Rank 203 of 225



RealRate

The First AI Rating Agency

www.realrate.ai



PHARMACEUTICAL 2025

Sonnet Biotherapeutics Holdings Inc Rank 203 of 225



The relative strengths and weaknesses of Sonnet Biotherapeutics Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonnet Biotherapeutics Holdings Inc compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 25% points. The greatest weakness of Sonnet Biotherapeutics Holdings Inc is the variable Assets, reducing the Economic Capital Ratio by 122% points.

The company's Economic Capital Ratio, given in the ranking table, is 75%, being 140% points below the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	2,118
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,210
Liabilities, Non-Current	47
Other Assets	633
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	84
Other Revenues	4,347
Property and Equipment	21
Research and Development	5,737
Selling, General and Administrative Expense	6,131

Output Variable	Value in 1000 USD
Assets	2,771
Liabilities	3,257
Expenses	11,868
Revenues	4,347
Stockholders Equity	-486
Net Income	-7,437
Comprehensive Net Income	-7,437
BaseVar	11,163
ECR before LimitedLiability	-282%
Economic Capital Ratio	75%